Companies › Beam Therapeutics
5 active drug programs in 5 registered trials: 5 Phase 1; Hematology, Metabolic and endocrine, Oncology, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BEAM-201 Base editing CAR-T cell therapy | – | Phase 1 | Lymphoblastic Lymphoma | Dec 2026 |
| BEAM-301 In vivo base editor targeting G6PC1 c.247C>T allele via A:T-to-G:C base-pair substitution | G6PC1 | Phase 1 | Glycogen Storage Disease Type Ia | Dec 2027 |
| BEAM-101 Base edited CD34+ hematopoietic stem and progenitor cells (autologous) | – | Phase 1 | Sickle Cell Disease | Feb 2028 |
| BEAM-302 lipid nanoparticle (LNP)-based alpha-1 antitrypsin (AAT) gene therapy | SERPINA1 | Phase 1 | Alpha 1-Antitrypsin Deficiency | May 2028 |
| BEAM-103 Monoclonal antibody | – | Phase 1 | Healthy Subjects | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07304791 | BEAM-103 | Phase 1 | Healthy Subjects | Other | Jan 2026 |
| NCT05885464 | BEAM-201 | Phase 1 | Lymphoblastic Lymphoma | Oncology | Dec 2026 |
| NCT06735755 | BEAM-301 | Phase 1 | Glycogen Storage Disease Type Ia | Genitourinary | Dec 2027 |
| NCT05456880 | BEAM-101 | Phase 1 | Sickle Cell Disease | Hematology | Feb 2028 |
| NCT06389877 | BEAM-302 | Phase 1 | Alpha 1-Antitrypsin Deficiency | Metabolic and endocrine | May 2028 |
Cash and short-term investments of $1.0bn on 2026-09-30; operating cash outflow about $410m a year; runway about 29 months at that burn, to Mar 2029
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Krystal Biotech Takeda Tessera Therapeutics Wave Life Sciences USA Grifols Therapeutics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.